Novo Nordisk A/S (NYSE:NVO) Trading Up 0.4% – Should You Buy?

Novo Nordisk A/S (NYSE:NVO) was up 0.4% during mid-day trading on Thursday . The stock traded as high as $81.43 and last traded at $80.86. Approximately 1,710,374 shares changed hands during trading, a decline of 80% from the average daily volume of 8,405,317 shares. The stock had previously closed at $80.57.

Analyst Ratings Changes

A number of analysts have commented on NVO shares. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Trading Up 0.8 %

The stock’s 50 day moving average is $96.10 and its two-hundred day moving average is $115.79. The company has a market capitalization of $364.30 billion, a PE ratio of 26.29, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Hedge Funds Weigh In On Novo Nordisk A/S

Large investors have recently bought and sold shares of the business. Natixis Advisors LLC lifted its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S during the fourth quarter worth about $4,066,000. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $86,000. Finally, Zions Bancorporation N.A. grew its position in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares during the period. Institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.